The current status of opioid maintenance treatment in France: A survey of physicians, patients, and out-of-treatment opioid users

International Journal of General Medicine

Volumn 7, Issue , 2014, Pages 449-457

  Benyamina, Amine ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

Buprenorphine; Buprenorphine naloxone; France; Medication assisted treatment; Methadone; Opioid maintenance treatment

Indexed keywords

DIAMORPHINE;

ADULT; ARTICLE; DRUG MISUSE; FEMALE; FRANCE; HEALTH CARE POLICY; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PATIENT CARE; PATIENT COUNSELING; PATIENT SATISFACTION; PHYSICIAN; SOCIAL SUPPORT; TOTAL QUALITY MANAGEMENT; TREATMENT PLANNING;

EID: 84907193155     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/IJGM.S61014     Document Type: Article

References (29)

1. World Health Organization; United Nations Office on Drugs and Crime; United Nations Programme on HIV/AIDS. WHO/UNODC/UNAIDS Position Paper: Substitution Maintenance Therapy in the Management of Opioid Dependence and HIV/AIDS Prevention. Geneva: World Health Organization; 2004. Available from: http://www. who. int/substance_abuse/activities/treatment_opioid_dependence/en. Accessed May 9, 2014.
2. Year of introduction of methadone maintenance treatment, high-dosage buprenorphine treatment, buprenorphine/naloxone combination, heroin-assisted treatment and slow-release morphine [webpage on the Internet]. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2012. Available from: http://www. emcdda. europa. eu/stats12#display:/stats12/hsrtab1. Accessed May 9, 2014.
3. Drug treatment overview for France [webpage on the Internet]. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2013. Available from: http://www. emcdda. europa. eu/data/treatment-overviews/France. Accessed May 9, 2014.
4. Circulaire DGS/DHOS n° 2002-57 du 30 janvier 2002 relative à la prescription de la méthadone par les médecins exerçant en établissement de santé, dans le cadre de l'initialisation d'un traitement de substitution pour les toxicomanes dépendants majeurs aux opiacés [DGC/DHOS Circular n° 2000-57, January 30, 2002 relative to methadone prescription by physicians who practice within health institutions, within the framework of initiating substitution treatment in patients with major opiate dependence] [webpage on the Internet]. France: Bureau SD 6 B; 2002. Available from: http://www. sante. gouv. fr/fichiers/bo/2002/02-08/a0080670. htm. Accessed January 19, 2014. French.
5. Fatseas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Curr Psychiatry Rep. 2007; 9(5): 358-364.
6. National drug strategies: France [webpage on the Internet]. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2012. Available from: http://www. emcdda. europa. eu/countries/national-drug-strategies/france. Accessed May 9, 2014.
7. Duburcq A, Charpak Y, Blin P, Madec L. [Two years follow-up of a heroin users cohort treated with high dosage buprenorphine. Results of the SPESUB study (pharmacoepidemiologic follow-up of general practice Subutex)]. Rev Epidemiol Sante Publique. 2000; 48(4): 363-373. French [with English abstract].
8. De Ducla M, Gagnon A, Mucchielli A, Robinet S, Vellay A. Comparison of high dose buprenorphine treatments of opiate dependent outpatients in four healthcare networks. Ann Med Interne (Paris). 2000; 151(Suppl B): B9-B15.
9. Fhima A, Henrion R, Lowenstein W, Charpak Y. [Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex)]. Ann Med Interne (Paris). 2001; 152(Suppl 3): IS26-IS36. French [with English abstract].
10. Emmanuelli J, Desenclos JC. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003. Addiction. 2005; 100(11): 1690-1700.
11. Roux P, Villes V, Bry D, et al. Buprenorphine sniffing as a response to inadequate care in substituted patients: results from the Subazur survey in south-eastern France. Addict Behav. 2008; 33(12): 1625-1629.
12. Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend. 2003; 69(2): 175-181.
13. Pauly V, Pradel V, Pourcel L, et al. Estimated magnitude of diversion and abuse of opioids relative to benzodiazepines in France. Drug Alcohol Depend. 2012; 126(1-2): 13-20.
14. Pradel V, Frauger E, Thirion X, et al. Impact of a prescription monitoring program on doctor-shopping for high dosage buprenorphine. Pharmacoepidemiol Drug Saf. 2009; 18(1): 36-43.
15. Fischer B, Bibby M, Bouchard M. The global diversion of pharmaceutical drugsnon-medical use and diversion of psychotropic prescription drugs in North America: a review of sourcing routes and control measures. Addiction. 2010; 105(12): 2062-2070.
16. Pauly V, Frauger E, Pradel V, et al. Which indicators can public health authorities use to monitor prescription drug abuse and evaluate the impact of regulatory measures? Controlling high dosage buprenorphine abuse. Drug Alcohol Depend. 2011; 113(1): 29-36.
17. Orman JS, Keating GM. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. Drugs. 2009; 69(5): 577-607.
18. Fischer G, Stöver H. Assessing the current state of opioid-dependence treatment across Europe: methodology of the European Quality Audit of Opioid Treatment (EQUATOR) project. Heroin Addict Relat Clin Probl. 2012; 14(3): 5-70.
19. Stöver H. Assessing the current state of public-health-related outcomes in opioid dependence across Europe: data from the EQUATOR analysis. Heroin Addict Relat Clin Probl. 2012; 14(4): 51-64.
20. Stöver H. Barriers to opioid substitution treatment access, entry and retention: a survey of opioid users, patients in treatment, and treating and non-treating physicians. Eur Addict Res. 2011; 17(1): 44-54.
21. Maremmani I. Foreword-EQUATOR publication series. Heroin Addict Relat Clin Probl. 2012; 14(4): 5-6.
22. Fischer G, Nava F, Stöver H. Outcomes of opioid-dependence treatment across Europe: identifying opportunities for improvement. Heroin Addict Relat Clin Probl. 2012; 14(4): 39-50.
23. Bell J, Shanahan M, Mutch C, et al. A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. Addiction. 2007; 102(12): 1899-1907.
24. Dale-Perera A, Goulao J, Stöver H. Quality of care provided to patients receiving Opioid Maintenance Treatment in Europe: Results from the EQUATOR analysis. Heroin Addict Relat Clin Probl. 2012; 14(4): 23-38.
25. Alho H, Sinclair D, Vuori E, Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007; 88(1): 75-78.
26. Larance B, Degenhardt L, Lintzeris N, et al. Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing. Drug Alcohol Depend. 2011; 118(2-3): 265-273.
27. Feroni I, Peretti-Watel P, Masut A, Coudert C, Paraponaris A, Obadia Y. French general practitioners' prescribing high-dosage buprenorphine maintenance treatment: is the existing training (good) enough? Addict Behav. 2005; 30(1): 187-191.
28. Bacha J, Reast S, Pearlstone A. Treatment practices and perceived challenges for European physicians treating opioid dependence. Heroin Addict Relat Clin Probl. 2010; 112(3): 9-19.
29. EMCDDA mission [webpage on the Internet]. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2010. Available from: http://www. emcdda. europa. eu/about/mission. Accessed May 9, 2014.